Cindy K. Miranti, PhD

Professor, Cellular and Molecular Medicine

Professor, BIO5 Institute

Chair, Cancer Biology Graduate Interdisciplinary Program

520-626-2269

cmiranti@arizona.edu

Links

Department Profile

NCBI Bibliography

Additional Link (lab link)

Biography

Cindy K. Miranti earned her B.Sc. in Microbiology from Southern Illinois University and Master’s in Microbiology from Colorado State University. She obtained her Ph.D in Biochemistry from Harvard Medical School. She completed her postdoctoral training at ARIAD Pharmaceuticals and Harvard Medical School. She joined the Van Andel Research Institute as an Assistant Professor and then Associate Professor. In 2016, she moved to University of Arizona as Professor of Cellular and Molecular Medicine. She is Leader of the Prostate Cancer Research Group, and Chair of the Cancer Biology Graduate Interdisciplinary Program.

Cancer Focus

My laboratory investigates how cell adhesion through integrins, controls the interactions of tumor cells with the surrounding tissues, and how they influence prostate cancer development, drug resistance, and bone metastasis. Our research is focused in three primary areas: 1) developing in vitro and in vivo models that recapitulate human disease based on clinical pathology, 2) identifying pathways and molecules that could serve as clinical markers and/or therapeutic targets, and 3) defining the genetic events involved in normal prostate and bone development to determine how they are disrupted by cancer.

Research Program Role

Cancer Biology Program

Display Name
Cindy K. Miranti, PhD

Publications

Nollet EA, Cardó-Vila M, Ganguly SS, Tran JD, Schulz VV, Cress A, Corey E, Miranti CK. 2020. Androgen receptor-induced integrin α6β1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer. Oncogene. 39:5390–5404. doi:10.1038/s41388-020-1370-9.

Miranti CK, Moore S, Kim Y, Chappeta VR, Wu K, De B, Gokhale V, Hurley LH, Reyes-Reyes EM. 2020. Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex. Oncotarget. 11:1758–1776. doi:10.18632/oncotarget.27589.

Ganguly SS, Hostetter G, Tang L, Frank SB, Saboda K, Mehra R, Wang L, Li X, Keller ET, Miranti CK. 2020. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3. Oncogene. 39:204–218. doi:10.1038/s41388-019-0977-1.

Jiang L, Ivich F, Tahsin S, Tran M, Frank SB, Miranti CK, Zohar Y. 2019. Human stroma and epithelium co-culture in a microfluidic model of a human prostate gland. Biomicrofluidics. 13:064116. doi:10.1063/1.5126714.

Rubenstein CS, Gard JMC, Wang M, McGrath JE, Ingabire N, Hinton JP, Marr KD, Simpson SJ, Nagle RB, Miranti CK, et al. 2019. Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate Cancer. Cancer Res. 79:4703–4714. doi:10.1158/0008-5472.CAN-19-0868.

Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, et al. 2019. Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. Am J Clin Exp Urol. 7:297–312.

Bergsma A, Ganguly SS, Dick D, Williams BO, Miranti CK. 2018. Global deletion of tetraspanin CD82 attenuates bone growth and enhances bone marrow adipogenesis. Bone. 113:105–113. doi:10.1016/j.bone.2018.05.020.

Das L, Gard JMC, Prekeris R, Nagle RB, Morrissey C, Knudsen BS, Miranti CK, Cress AE. 2018. Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer. Mol Cancer Res. 16:1319–1331. doi:10.1158/1541-7786.MCR-17-0589.

Frank SB, Berger PL, Ljungman M, Miranti CK. 2017. Human prostate luminal cell differentiation requires NOTCH3 induction by p38-MAPK and MYC. J Cell Sci. 130:1952–1964. doi:10.1242/jcs.197152.

Frank SB, Schulz VV, Miranti CK. 2017. A streamlined method for the design and cloning of shRNAs into an optimized Dox-inducible lentiviral vector. BMC Biotechnol. 17:24. doi:10.1186/s12896-017-0341-x.

Berger PL, Winn ME, Miranti CK. 2017. Miz1, a Novel Target of ING4, Can Drive Prostate Luminal Epithelial Cell Differentiation. Prostate. 77:49–59. doi:10.1002/pros.23249.

Tesfay L, Schulz VV, Frank SB, Lamb LE, Miranti CK. 2016. Receptor tyrosine kinase Met promotes cell survival via kinase-independent maintenance of integrin α3β1. Mol Biol Cell. 27:2493–504. doi:10.1091/mbc.E15-09-0649.